Result of Annual Shareholders Meeting, Agreements, FDA Approval, Scheduled Conferences, and Dividends - Analyst Notes on Valeant Pharmaceuticals, Novartis, Teva, PTC Therapeutics and Agilent

NEW YORK, May 28, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Valeant Pharmaceuticals Intl Inc (NYSE: VRX), Novartis AG (ADR) (NYSE: NVS), Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA), PTC Therapeutics, Inc. (NASDAQ: PTCT) and Agilent Technologies Inc. (NYSE: A). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3009-100free.

Valeant Pharmaceuticals Intl Inc Analyst Notes
On May 21, 2014, Valeant Pharmaceuticals Intl Inc (Valeant Pharmaceuticals) held the Company's 2014 annual meeting of shareholders and elected ten directors. According to the Company, during the annual meeting shareholders also appointed PricewaterhouseCoopers LLP (United States) as the Company's independent registered public accounting firm until the close of Company's 2015 annual meeting of shareholders; approved the non-binding advisory vote on named executive officer compensation as discussed in the proxy statement; and also approved the 2014 Omnibus Incentive Plan and the authorization and approval of the 320,033 share units grants and 180,000 options, which were made subject to the shareholder approval of the 2014 Plan. The full analyst notes on Valeant Pharmaceuticals are available to download free of charge at:

http://www.analystsreview.com/VRX.pdf/Register

Novartis AG (ADR) Analyst Notes
On May 19, 2014, Novartis AG (ADR) (Novartis) announced the signing of a licensing and commercialization agreement with Ophthotech Corporation (Ophthotech) for the exclusive rights to market Fovista® (anti-PDGF aptamer) outside the U.S. Novartis stated that, Fovista® is being studied in combination with anti-VEGF agents for patients going through wet age-related macular degeneration (wet AMD). Under the financial terms of the agreement, Ophthotech will be given an immediate payment of an upfront fee of USD 200.0 million alongwith potential future recruitment and other milestone payments. The Company added that Ophthotech will hold the marketing rights to Fovista® in the U.S and is also eligible to receive royalties on ex-US Fovista® sales. Additionally, with a Novartis proprietary anti-VEGF treatment, Novartis will develop a co-formulation of Fovista®. The full analyst notes on Novartis are available to download free of charge at:

http://www.analystsreview.com/NVS.pdf/Register

Teva Pharmaceutical Industries Ltd (ADR) Analyst Notes
On May 23, 2014, Teva Pharmaceutical Industries Ltd (ADR) (Teva) announced that U.S. Food and Drug Administration (FDA) has approved the use of QVAR® (beclomethasone dipropionate HFA) equipped with a dose counter for the ongoing treatment of asthma patients age five and older as a preventative therapy. Teva stated that QVAR® is an inhaled corticosteroid (ICS) and recommended as a twice-daily treatment for long-term asthma control. According to the Company, the new product will be available later in 2014. "Bringing QVAR® with a dose counter to market reaffirms Teva's commitment to addressing unmet needs by providing high-quality and innovative solutions to patients," said Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development. "Adding to our rich heritage within the respiratory space, we are pleased that all Teva Respiratory brands in the U.S. will soon include a dose counter, which will help patients and caregivers track how many doses of their medication remain." The full analyst notes on Teva are available to download free of charge at:

http://www.analystsreview.com/TEVA.pdf/Register

PTC Therapeutics, Inc. Analyst Notes
On May 21, 2014, PTC Therapeutics, Inc. (PTC Therapeutics) announced that the Company will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4, 2014, at 2:00 p.m. ET, at the Grand Hyatt in New York City. According to PTC Therapeutics, the presentation will be webcast live at its website, and will also be archived for two weeks after the presentation. The full analyst notes on PTC Therapeutics are available to download free of charge at:

http://www.analystsreview.com/PTCT.pdf/Register

Agilent Technologies Inc. Analyst Notes
On May 22, 2014, Agilent Technologies Inc. (Agilent ) announced a quarterly dividend of 13.2 cents per share of common stock. The Company informed that the dividend is payable on July 23, 2014, to all shareholders of record at the close of business on July 1, 2014. The full analyst notes on Agilent are available to download free of charge at:

http://www.analystsreview.com/A.pdf/Register

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED